^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

NKTR-255

i
Other names: NKTR-255
Company:
Nektar Therap
Drug class:
IL-15R agonist
2ms
Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy. (PubMed, J Immunother Cancer)
Our preclinical studies demonstrate that immunotherapy via the innate immune system by combining tumor-targeting CAR-NK cells with an IL-15 agonist and a CD47 blockade is a promising novel therapeutic approach to targeting MCAMhigh malignant metastatic ES.
Journal • IO biomarker
|
IFNG (Interferon, gamma) • MCAM (Melanoma Cell Adhesion Molecule) • IL15 (Interleukin 15)
|
MCAM expression
|
magrolimab (ONO-7913) • NKTR-255
4ms
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) (clinicaltrials.gov)
P2, N=256, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy • Metastases
|
Bavencio (avelumab) • Trodelvy (sacituzumab govitecan-hziy) • NKTR-255 • dargistotug (M6223)
4ms
A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia. (PubMed, Blood)
The increase in chemokines was associated with decreases in absolute lymphocyte counts and CD8+ CAR T-cells in blood and ten-fold increases in CSF CAR-T cells, suggesting lymphocyte trafficking to tissue. Combining NKTR-255 with CAR19-22 was safe, feasible and associated with high rates of durable responses (NCT03233854).
P1 data • Journal • CAR T-Cell Therapy
|
CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CD22 (CD22 Molecule) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • IL15 (Interleukin 15)
|
NKTR-255
6ms
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors (clinicaltrials.gov)
P1/2, N=25, Completed, Nektar Therapeutics | Phase classification: P1b/2 --> P1/2
Phase classification • Combination therapy
|
PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
|
Erbitux (cetuximab) • NKTR-255
9ms
C-TIL051 in Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=20, Recruiting, AbelZeta, Inc. | Not yet recruiting --> Recruiting
Enrollment open
|
Keytruda (pembrolizumab) • NKTR-255
9ms
Enrollment closed
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 positive • CD19 expression • CD22 expression
|
cyclophosphamide • fludarabine IV • NKTR-255
9ms
NCI-2022-02316: NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma (clinicaltrials.gov)
P1, N=24, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jan 2024 --> Dec 2024
Trial completion date • Trial primary completion date • Combination therapy • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 expression
|
cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • fludarabine IV • NKTR-255
11ms
C-TIL051 in Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=20, Not yet recruiting, AbelZeta, Inc.
Trial completion date • Trial primary completion date • Metastases
|
Keytruda (pembrolizumab) • NKTR-255
1year
Optimizing Ex-Vivo Expanded NK Cell- Mediated Cellular Cytotoxicity By Obinutuzumab Combined with NKTR-255 in Burkitt Lymphoma (BL) (ASH 2023)
NKTR-255 is an IL-15 receptor agonist designed to activate the IL-15 pathway and NK cells and promote the survival and expansion of memory CD8+ T cells without inducing suppressive regulatory T cells (Kuo/Zalevsky, Cancer Res. We found that NKTR-255 significantly enhanced the ADCC of expanded NK cells with Obinutuzumab against rituximab-resistant BL cells in vitro with enhanced IFN- g, granzyme B and perforin release. The in vivo effects of NKTR-255 with expanded NK cells and Obinutuzumab against rituximab-resistant BL cells using humanized NSG models are very promising. Mechanisms studies of BL relapsed from the combination therapy are under investigation.
Preclinical • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • GZMB (Granzyme B) • GZMA (Granzyme A) • IL15 (Interleukin 15) • IL21 (Interleukin 21)
|
Rituxan (rituximab) • Gazyva (obinutuzumab) • NKTR-255
1year
The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma. (PubMed, Future Oncol)
Overall, 252 patients with advanced UC who are progression-free following first-line platinum-based chemotherapy will be randomized 1:2:2:2 to receive maintenance therapy with avelumab alone (control group) or combined with sacituzumab govitecan (anti-Trop-2/topoisomerase inhibitor conjugate), M6223 (anti-TIGIT) or NKTR-255 (recombinant human IL-15). Primary end points are progression-free survival per investigator and safety/tolerability of the combination regimens. Secondary end points include overall survival, objective response and duration of response per investigator, and pharmacokinetics.
Review • Journal • Metastases
|
TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
Bavencio (avelumab) • Trodelvy (sacituzumab govitecan-hziy) • NKTR-255 • dargistotug (M6223)
over1year
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=30, Completed, Nektar Therapeutics | Active, not recruiting --> Completed
Trial completion
|
Rituxan (rituximab) • NKTR-255 • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
over1year
REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) (clinicaltrials.gov)
P2, N=39, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Apr 2023 --> Jan 2023
Enrollment open • Trial initiation date
|
Imfinzi (durvalumab) • NKTR-255
over1year
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors (clinicaltrials.gov)
P1b/2, N=25, Completed, Nektar Therapeutics | Active, not recruiting --> Completed | N=326 --> 25 | Trial completion date: Aug 2024 --> Mar 2023
Trial completion • Enrollment change • Trial completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
Erbitux (cetuximab) • NKTR-255
over1year
TARGETING EWING SARCOMA WITH ANTI-IL1RAP CHIMERIC ANTIGEN RECEPTOR MODIFIED EX-VIVO EXPANDED NATURAL KILLER CELLS (IL1RAP-CAR NK) AND TGF-BETA IMPRINTED NK CELLS (CAR TGFBI NK) IN COMBINATION WITH DINUTUXIMAB AND NKTR-25 (ASPHO 2023)
Our data provide a ra onale for a preclinical evalua on of IL1RAP-CAR NK/TGFbi-NK combined with NKTR-255 and dinutuximab in limi ng ES xenogra tumor growth and/or metastasis and prolonging animal survival in-vivo. Count: 400 words (Limit 400 words) This study was funded by NCI Cancer Moonshot U54 grant (CA232561-01A1).
Preclinical • Combination therapy • IO biomarker
|
IFNG (Interferon, gamma) • TGFB1 (Transforming Growth Factor Beta 1) • IL1RAP (Interleukin 1 Receptor Accessory Protein) • TGFBI (Transforming Growth Factor Beta Induced)
|
NKTR-255 • Unituxin (dinutuximab)
over1year
TARGETING GLIOBLASTOMA & DIFFUSE INTRINSIC PONTINE GLIOMA W/ ANTI-GD2 CAR MODIFIED NK CELLS (ASPHO 2023)
Our data demonstrated successful engineering of anti-GD2 CAR NK cells and increased cytotoxic capacity in the anti-GD2 CAR NK when compared to the mock NK cell. We plan to test the anti- GD2 CAR NK cells on the GD2+ M054K GBM cell line and a GD2+ DIPG cell line. Afterwards, we will test the synergistic effect of the combination of NKTR-255 and anti-ROR1 antibody with the CAR NK cells against the same cell lines.
IO biomarker
|
IL2 (Interleukin 2) • IL15 (Interleukin 15)
|
NKTR-255
over1year
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=30, Active, not recruiting, Nektar Therapeutics | Enrolling by invitation --> Active, not recruiting | N=118 --> 30 | Trial completion date: Oct 2023 --> Jun 2023 | Trial primary completion date: Mar 2023 --> Jun 2023
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
Rituxan (rituximab) • NKTR-255 • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
over1year
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors (clinicaltrials.gov)
P1b/2, N=326, Active, not recruiting, Nektar Therapeutics | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
Erbitux (cetuximab) • NKTR-255
over1year
B7-H3 blockade in combination with natural killer cell activity enhancers including NKTR-255 and venetoclax synergistically induces cytotoxicity in B7-H3+ AML cells (AACR 2023)
Our data demonstrate that blockade of the immune checkpoint protein, B7-H3 with the IL-15 receptor agonist, NKTR-255, or the BCL2 inhibitor, ABT-199, synergistically induces NK cell mediated cytotoxicity against B7-H3+ AML cells.
Combination therapy • IO biomarker
|
CD276 (CD276 Molecule) • NKG2D (killer cell lectin like receptor K1)
|
Venclexta (venetoclax) • NKTR-255
over1year
NKTR-255, a polymer-conjugated IL-15, dramatically improves ROR1 CAR-T cell persistence and anti-tumor efficacy in an autochthonous model of ROR1+ lung cancer (AACR 2023)
Together, our work shows that NKTR-255 dramatically improves the persistence, function, and anti-tumor activity of ROR1 CAR-T cells in an aggressive autochthonous model of ROR1+ lung cancer. Our findings provide rationale to combine NKTR-255 with CAR-T cell therapy as a strategy to enhance the anti-tumor efficacy of CAR-T cells in patients with solid tumors.
Clinical • CAR T-Cell Therapy • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • IL2 (Interleukin 2) • IL15 (Interleukin 15)
|
KRAS G12D • KRAS G12 • ROR1 expression • KRAS expression
|
NKTR-255
almost2years
Enrollment open • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 expression
|
NKTR-255
almost2years
New P2/3 trial • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 expression
|
NKTR-255
almost2years
Early Results of a Phase I Study of CAR-T Cells + NKTR-255 (PEG-IL-15) in Adults with R/R ALL (TCT-ASTCT-CIBMTR 2023)
Following lymphodepletion with fludarabine and cyclophosphamide, patients received the recommended Phase 2 dose of 3.0 x 10 6 /kg CAR-T cells (Spiegel, Patel, Muffly et al, Nature Medicine 2021). NKTR-255 administered at 1.5mcg/kg following CAR-T cell therapy was safe and appeared to promote CAR expansion in CNS and peripheral blood. Dose escalation is ongoing; additional safety data and longitudinal correlative assessments, including qPCR and cytokine data, will be presented at the meeting.
Clinical • P1 data • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • IL15 (Interleukin 15)
|
cyclophosphamide • fludarabine IV • NKTR-255
almost2years
A Phase Ib Open-Label Study Evaluating the Safety and Efficacy of NKTR-255 in Combination with CD19-Directed CAR-T Cell Therapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) (ASH 2022)
Subjects will receive lymphodepletion chemotherapy with cyclophosphamide and fludarabine followed by liso-cel infusion per Breyanzi® package insert, and NKTR-255 at 1.5 µg/kg intravenously every 3 weeks starting at approximately 10 to 14 days after CAR-T cell infusion. Conclusion s : This clinical trial will evaluate the safety and efficacy of NKTR-255 in combination with liso-cel aiming to increase the response rates and durability of response compared with CD19 CAR-T cells alone. Based on the biological rationale of IL-15 supplementation, correlative data from CD19 CAR-T cell studies, and results from preclinical studies with xenogeneic mouse models, NKTR-255 has the potential to augment currently approved cellular therapies.
Clinical • P1 data • Combination therapy • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • IL15 (Interleukin 15)
|
cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • fludarabine IV • NKTR-255
2years
A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR-T cell immunotherapy. (PubMed, Blood Adv)
These data support an ongoing phase I clinical trial of combined CD19 CAR-T and NKTR-255 for R/R B-cell malignancies. This trial is registered at www.clinicaltrials.gov as NCT01865617.
Journal • CAR T-Cell Therapy • IO biomarker
|
CD19 (CD19 Molecule) • IL15 (Interleukin 15)
|
NKTR-255
2years
Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies (ASH 2022)
In preclinical studies, NKTR-255 enhanced antibody-dependent cellular cytotoxicity (ADCC) of daratumumab, rituximab, and cetuximab, resulting in synergistic antitumor effect. This ongoing Phase 1 trial (NCT04136756) evaluates safety, tolerability, pharmacokinetics (PK) and PD of NKTR-255 monotherapy and with subcutaneous (SC) Darzalex-Faspro (dara) or rituximab in patients with hematologic malignancies... In heavily pretreated patients with heme malignancies NKTR-255, alone and with SC dara was well-tolerated, manageable and biologically active with sustained increases in NK and CD8+ T cells. NKTR-255 administration replenished dara-induced NK cell depletion. Optimal biological response of NKTR-255 monotherapy was observed between 6-9 µg/kg and will be further tested in Phase 2.
Clinical • PK/PD data • IO biomarker
|
CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL15 (Interleukin 15)
|
Erbitux (cetuximab) • Rituxan (rituximab) • NKTR-255 • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
2years
A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ASH 2022)
Eligible patients who have r/r large B-cell lymphoma and are planned for treatment with an FDA-approved CAR-T product (axi-cel or liso-cel) will be enrolled...The key eligibility criteria following CD19 targeted CAR-T cell infusion include no grade ≥ 1 cytokine release syndrome (CRS) on the day of NKTR-255 administration, no grade ≥ 3 CRS within 72 hours proceeding NKTR-255 administration, no grade ≥ 3 immune effector cell-associated neurotoxicity (ICANS) of > 72 hours duration, no grade ≥ 2 ICANS on the day of NKTR-255 infusion and no tocilizumab and/or dexamethasone within 48 hours proceeding NKTR-255 administration. Based on preclinical and clinical evidence, NKTR-255 has the potential to improve efficacy of currently approved cellular therapies. This trial evaluates safety and efficacy of NKTR-255 following commercial CD19 CAR-T therapy to enhance antitumor effect and durability of responses.
Clinical • P2/3 data
|
CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • IL15 (Interleukin 15)
|
CD19 expression
|
Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • dexamethasone • NKTR-255 • Actemra IV (tocilizumab)
2years
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=118, Enrolling by invitation, Nektar Therapeutics | Recruiting --> Enrolling by invitation | Trial completion date: Jan 2023 --> Oct 2023 | Trial primary completion date: Jun 2022 --> Mar 2023
Enrollment status • Trial completion date • Trial primary completion date
|
CD19 (CD19 Molecule)
|
Rituxan (rituximab) • NKTR-255 • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
2years
Enrollment open • Combination therapy • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 expression
|
cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • fludarabine IV • NKTR-255
over2years
Improving NK Cell Function in Multiple Myeloma with NKTR-255, a Novel Polymer-Conjugated Human IL-15. (PubMed, Blood Adv)
Finally, we observed that combination of NKTR-255 with the anti-CD38 antibody, daratumumab, was effective against MM cells in vitro and in vivo. Taken together, our data suggest a significant impact of NKTR-255 in inducing NK cell function against MM cells with important translational implications.
Journal • IO biomarker
|
IL15 (Interleukin 15)
|
Darzalex (daratumumab) • NKTR-255
over2years
NCI-2022-02316: NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma (clinicaltrials.gov)
P1, N=24, Not yet recruiting, Fred Hutchinson Cancer Center | Initiation date: May 2022 --> Nov 2022
Trial initiation date • Combination therapy • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 expression
|
cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • fludarabine IV • NKTR-255
over2years
New P1 trial • Combination therapy • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 expression
|
cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • fludarabine IV • NKTR-255
almost3years
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors (clinicaltrials.gov)
P1b/2, N=326, Recruiting, Nektar Therapeutics | N=78 --> 326 | Trial completion date: Apr 2023 --> Aug 2024 | Trial primary completion date: Apr 2022 --> Jun 2023
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
Erbitux (cetuximab) • NKTR-255
3years
Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies (ASH 2021)
In preclinical studies, NKTR-255 enhanced antibody-dependent cellular cytotoxicity (ADCC) of each of daratumumab, rituximab, trastuzumab, and cetuximab, resulting in synergistic anticancer activity. In this heavily pretreated relapsed/refractory patient population with hematologic malignancies, NKTR-255 was biologically active, and demonstrated sustained increases in NK and CD8 + T cells. NKTR-255 was well tolerated with minimal treatment-related toxicities and transient upregulation and rapid decline of cytokines to baseline levels. RP2D for NKTR-255 monotherapy has not yet been reached; and dose escalation is ongoing at 9.0 µg/kg.
Clinical • PK/PD data
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • CCL2 (Chemokine (C-C motif) ligand 2)
|
Herceptin (trastuzumab) • Erbitux (cetuximab) • Rituxan (rituximab) • Darzalex (daratumumab) • NKTR-255
3years
Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8+ T-Cells: Preliminary Results from a Phase 1 Study (ASH 2021)
Following treatment with NKTR-255, there was an increase in CAR-T-cells as well as a reversal of the CD4 + :CD8 + ratio in 1 patient. Additionally, NKTR-255 induced expansion of total CD8 + cell fraction with an increase of proliferation index of Ki67 in all reported patients, supporting its role in enhancing the expansion and proliferative ability of cytotoxic T cells. Low baseline CAR-T/CAR-NK cell counts observed in patients may be due to longer time intervals between CAR-T infusion and the first dose of NKTR-255.
Clinical • P1 data • PK/PD data • CAR T-Cell Therapy • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
CD19 expression
|
NKTR-255
3years
[VIRTUAL] Improving NK Cell Function in Multiple Myeloma with NKTR-255, a Novel Polymer- Conjugated Human IL-15 (IMW 2021)
Taken together, these results support the restoration and expansion of NK cell activity in MM with NKTR-255, providing rationale for its clinical use as a novel immunotherapeutic approach for MM patients alone or in combination with monoclonal antibodies or other immunomodulatory drugs.
IO biomarker
|
CD69 (CD69 Molecule) • SDC1 (Syndecan 1) • NKG2D (killer cell lectin like receptor K1)
|
Darzalex (daratumumab) • NKTR-255
3years
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=118, Recruiting, Nektar Therapeutics | Trial completion date: Sep 2022 --> Jan 2023
Clinical • Trial completion date
|
CD19 (CD19 Molecule)
|
Rituxan (rituximab) • NKTR-255 • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
over3years
NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy. (PubMed, J Immunother Cancer)
Our results show that the novel immunotherapeutic, NKTR-255, retains the full spectrum of IL-15 biology, but with improved PK properties, over rhIL-15. These findings support the ongoing phase 1 first-in-human trial (NCT04136756) of NKTR-255 in participants with relapsed or refractory hematologic malignancies, potentially advancing rhIL-15-based immunotherapies for the treatment of cancer.
Clinical • Journal
|
CD8 (cluster of differentiation 8) • GZMB (Granzyme B)
|
NKTR-255 • rhIL-15
almost4years
Clinical • Enrollment change
|
CD19 (CD19 Molecule)
|
Rituxan (rituximab) • NKTR-255 • Darzalex Faspro (daratumumab and hyaluronidase-fihj)